MARKET

HELP

HELP

Helus Pharma Inc
NASDAQ
8.39
-0.29
-3.34%
Pre Market: 8.45 +0.06 +0.72% 08:39 11/06 EST
OPEN
8.55
PREV CLOSE
8.68
HIGH
8.75
LOW
8.20
VOLUME
1.61K
TURNOVER
0
52 WEEK HIGH
15.15
52 WEEK LOW
3.760
MARKET CAP
612.97M
P/E (TTM)
-1.9740
1D
5D
1M
3M
1Y
5Y
1D
Helus Pharma Co-Founders Leave Executive Roles as Mark Lawson Becomes Independent Chair
TipRanks · 1h ago
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 21h ago
Helus Pharma Announces CEO Participation at Healthcare Innovation Conference
TipRanks · 2d ago
COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission
Seeking Alpha · 3d ago
Barclays Remains a Buy on Helus Pharma (HELP)
TipRanks · 3d ago
Compass’ robust clinical data can support pricing power, says Jefferies
TipRanks · 3d ago
Usona psilocybin filing has implications for Compass, Definium, says Canaccord
TipRanks · 3d ago
Weekly Report: what happened at HELP last week (1026-1030)?
Weekly Report · 4d ago
More
About HELP
Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are intended to address the unmet need for people who suffer from depression, anxiety, and other mental health conditions. The Company is developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. It has developed EMBARK, which incorporates evidence-based therapies (EBTs), empirically supported treatments (ESTs), and provides session monitors with the training needed to support participants safely and effectively through treatment sessions in clinical trials. Its other pipeline product in development is HLP005.

Webull offers Helus Pharma Inc. stock information, including NASDAQ: HELP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HELP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HELP stock methods without spending real money on the virtual paper trading platform.